open access

Vol 25, No 3 (2020)
Original research articles
Published online: 2020-05-01
Submitted: 2019-10-18
Get Citation

Impact of bone events on survival in solitary bone plasmacytoma

Geovanne Pedro Mauro, Pedro Pereira Neffá, Rosangela Correa Villar, Gracia Aparecida Martinez, Heloísa de Carvalho
DOI: 10.1016/j.rpor.2020.04.002
·
Rep Pract Oncol Radiother 2020;25(3):389-395.

open access

Vol 25, No 3 (2020)
Original research articles
Published online: 2020-05-01
Submitted: 2019-10-18

Abstract

Background

Although much studied in multiple myeloma, bone events (BE) can also cause important morbidity in bone plasmacytoma patients. To our knowledge, the effect of BE on overall survival (OS) and progression to multiple myeloma free-survival (MPFS) also has never been studied.

Patients and Methods

Fifty-nine patients treated from 2008 to 2017 were retrospectively assessed. All patients had histological proof of disease and were treated with radical radiotherapy (RT). Available clinical information for at least 6 months follow-up or until death had to be available. BE were described as one of the following events in the index bone: fractures, osteomyelitis, chronic pain, surgery or loss of limb function after RT.

Results

Mean age at diagnosis was 57.3 years (18–80); most male (67.8%). Mean OS, bone event free-survival (BEFS), local progression-free survival (LPFS) and MPFS were 41, 36, 37 and 19 months, respectively. There were 15 deaths. BEFS (p = 0.008) and age>55y (p = 0.044) were associated with MPFS. Only BEFS correlated with OS (p = 0.029). BE was independently associated with both MPFS and OS in multivariate analysis.

Conclusion

BE and survival end-points were correlated. BE should be investigated in prospective trials.

Abstract

Background

Although much studied in multiple myeloma, bone events (BE) can also cause important morbidity in bone plasmacytoma patients. To our knowledge, the effect of BE on overall survival (OS) and progression to multiple myeloma free-survival (MPFS) also has never been studied.

Patients and Methods

Fifty-nine patients treated from 2008 to 2017 were retrospectively assessed. All patients had histological proof of disease and were treated with radical radiotherapy (RT). Available clinical information for at least 6 months follow-up or until death had to be available. BE were described as one of the following events in the index bone: fractures, osteomyelitis, chronic pain, surgery or loss of limb function after RT.

Results

Mean age at diagnosis was 57.3 years (18–80); most male (67.8%). Mean OS, bone event free-survival (BEFS), local progression-free survival (LPFS) and MPFS were 41, 36, 37 and 19 months, respectively. There were 15 deaths. BEFS (p = 0.008) and age>55y (p = 0.044) were associated with MPFS. Only BEFS correlated with OS (p = 0.029). BE was independently associated with both MPFS and OS in multivariate analysis.

Conclusion

BE and survival end-points were correlated. BE should be investigated in prospective trials.

Get Citation

Keywords

Skeletal events; Plasmacytoma; Multiple myeloma progression; Morbidity; Bone disease

About this article
Title

Impact of bone events on survival in solitary bone plasmacytoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 3 (2020)

Pages

389-395

Published online

2020-05-01

DOI

10.1016/j.rpor.2020.04.002

Bibliographic record

Rep Pract Oncol Radiother 2020;25(3):389-395.

Keywords

Skeletal events
Plasmacytoma
Multiple myeloma progression
Morbidity
Bone disease

Authors

Geovanne Pedro Mauro
Pedro Pereira Neffá
Rosangela Correa Villar
Gracia Aparecida Martinez
Heloísa de Carvalho

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl